- Home
- MUJ vs LAB Comparison
MUJ vs LAB Comparison
Compare MUJ & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUJ
- LAB
- Stock Information
- Founded
- MUJ 1998
- LAB 1999
- Country
- MUJ United States
- LAB United States
- Employees
- MUJ N/A
- LAB N/A
- Industry
- MUJ Investment Bankers/Brokers/Service
- LAB Biotechnology: Laboratory Analytical Instruments
- Sector
- MUJ Finance
- LAB Industrials
- Exchange
- MUJ Nasdaq
- LAB Nasdaq
- Market Cap
- MUJ 573.3M
- LAB 562.1M
- IPO Year
- MUJ N/A
- LAB 2011
- Fundamental
- Price
- MUJ $10.81
- LAB $1.16
- Analyst Decision
- MUJ
- LAB Buy
- Analyst Count
- MUJ 0
- LAB 2
- Target Price
- MUJ N/A
- LAB $2.50
- AVG Volume (30 Days)
- MUJ 108.0K
- LAB 1.3M
- Earning Date
- MUJ 01-01-0001
- LAB 05-07-2025
- Dividend Yield
- MUJ 4.36%
- LAB N/A
- EPS Growth
- MUJ N/A
- LAB N/A
- EPS
- MUJ N/A
- LAB N/A
- Revenue
- MUJ N/A
- LAB $174,432,000.00
- Revenue This Year
- MUJ N/A
- LAB N/A
- Revenue Next Year
- MUJ N/A
- LAB $12.77
- P/E Ratio
- MUJ N/A
- LAB N/A
- Revenue Growth
- MUJ N/A
- LAB 64.03
- 52 Week Low
- MUJ $9.74
- LAB $0.97
- 52 Week High
- MUJ $11.70
- LAB $2.74
- Technical
- Relative Strength Index (RSI)
- MUJ 35.03
- LAB 50.69
- Support Level
- MUJ $10.50
- LAB $0.99
- Resistance Level
- MUJ $10.95
- LAB $1.18
- Average True Range (ATR)
- MUJ 0.19
- LAB 0.10
- MACD
- MUJ -0.02
- LAB 0.01
- Stochastic Oscillator
- MUJ 33.33
- LAB 86.36
About MUJ Blackrock MuniHoldings New Jersey Quality Fund Inc.
BlackRock MuniHoldings New Jersey Quality Fund Inc is a closed-end management investment company. The investment objective of the company is to provide shareholders with current income exempt from U.S. federal income tax and New Jersey personal income taxes. The fund invests in a portfolio of long-term, investment-grade New Jersey municipal obligations.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.